NCT04610957 is a NA clinical trial of Rosafem (FEMININE FORMULA) in Ovulation Induction, sponsored by FAlbasri.

Who is sponsoring NCT04610957?

NCT04610957 is sponsored by FAlbasri.

What drugs are being tested in NCT04610957?

Interventions in NCT04610957: Rosafem (FEMININE FORMULA).

What condition does NCT04610957 study?

NCT04610957 studies Ovulation Induction, Polycystic Ovary Syndrome.

Is NCT04610957 still recruiting?

NCT04610957 is currently completed. Last updated 2 November 2020.

Last reviewed 2020-11-02 · How we verify

NCT04610957

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Adding Isoflavonoids to Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome

Completed NA Last updated 2 November 2020

What this trial tests

NA trial testing Rosafem (FEMININE FORMULA) in Ovulation Induction in 160 participants. Completed in 10 April 2019.

Timeline

1 January 2019

Primary endpoint
1 January 2019

10 April 2019

Quick facts

Lead sponsor	FAlbasri
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	1 January 2019
Primary completion	1 January 2019
Estimated completion	10 April 2019
Sites	1 location across Egypt

Drugs / interventions tested

Rosafem (FEMININE FORMULA) — full drug profile →

Conditions studied

Ovulation Induction — all drugs for Ovulation Induction →
Polycystic Ovary Syndrome — all drugs for Polycystic Ovary Syndrome →

Sponsor

FAlbasri — full company profile →

Who can join

Adults 18 to 35, female only, with Ovulation Induction or Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, randomized clinical trial double blinded study, has been carried on 160 infertile patients seeking pregnancy in Gynecology and Obstetrics Department, Zagazig University Hospitals during the period from January 2019 to November 2019, the participants' randomizations were done and patients divided into two groups; group I: included 80 women receiving Clomiphene citrate (CC) plus Isoflavonoids. Group 2: included 80 women receiving Clomiphene citrate only

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ovulation Induction

Currently open trials in the same condition.

NCT06934785 — LE + CC vs. LE for Ovulation Induction · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04610957 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by FAlbasri
Last refreshed: 2 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04610957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing